Cutting Through The Junk - Targeting & Delivering Drugs through The Tumor Stroma

From the Laboratory of Lily Yang, Ph.D., Dept. of Surgery, Emory

Cliff Michaels, Senior Licensing Associate
OTT Breakfast Club, December 9th, 2014
Cancer
- 2nd leading cause of death in the US
- 8.2M deaths worldwide

Treatments
Traditional – Broadly active chemotherapies at high doses
New – Targeted, attacks tumor cells specifically

Unmet Need
Targeted drugs get to tumor site, but struggle to get through barrier around tumor cells
The Challenge

• Not homogeneous!
  – Lots of support cells – vascular cells, immune cells, fibroblast, etc.
  – Fibroblast secrete matrix proteins → Create a barrier

How do we deliver drugs to the tumor cells through the “junk”?
Our Technology

A fusion protein that both targets a drug & cuts through the barrier around the tumor cells

Enzyme degrades matrix protein barrier while targeting moiety directs drug to tumor cells
Does It Work?

Prior data showed the Emory Targeting Molecule Delivers Efficiently Deep into Tumors

Decreased tumor weights when Emory Targeting Molecule used to deliver Doxil (Janssen)
Value proposition

- Solution for major drug delivery challenge
  - Delivers drug to tumor & more drug to tumor cells
  - Potentially lower doses & less side effects
- Potential platform opportunity
- Promising proof of concept data

Next Steps – Continued mouse model experiment

IP Status – PCT application filed

Commercialization – We are actively seeking a commercial partner to develop further
Thank you!